NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

新型冠狀病毒感染疾病(COVID-19)的急性及慢性併發症的治療方法:目前市場分析及預測(2020年∼2030年)

Coronavirus Disease 2019 (COVID-19) - Curative Therapeutics for Acute & Chronic Complications with Current and Forecasted Market Analysis 2020 - 2030

出版商 GervanoRA Data Services LLP 商品編碼 1006861
出版日期 內容資訊 英文 379 Pages
商品交期: 最快1-2個工作天內
價格
新型冠狀病毒感染疾病(COVID-19)的急性及慢性併發症的治療方法:目前市場分析及預測(2020年∼2030年) Coronavirus Disease 2019 (COVID-19) - Curative Therapeutics for Acute & Chronic Complications with Current and Forecasted Market Analysis 2020 - 2030
出版日期: 2021年04月12日內容資訊: 英文 379 Pages
簡介

COVID-19開發平台藥物,從初期的研究開發階段在到核可階段的各種開發階段中有約920種治療藥和疫苗,這些開發中的藥物中,573個是治療藥,345個是疫苗。

本報告提供新型冠狀病毒感染疾病(COVID-19)的急性及慢性併發症的治療方法市場的相關調查,疾病概要,市場概要,開發平台分析,流行病學為基礎市場趨勢,世界及EU7(俄羅斯,英國,法國,義大利,西班牙,德國,波蘭),美國市場的詳細說明,市場機會,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

第2章 摘要整理

第3章 新型冠狀病毒感染疾病(COVID-19)的概要與流行病學研究

第4章 COVID-19競爭空間的交易分析

第5章 新型冠狀病毒感染疾病的開發平台藥物分析(COVID-19)

第6章 開發平台藥物概要與開發里程碑

第7章 COVID-19開發平台藥物估計核準時間軸

第8章 各競爭基準機會評估

第9章 COVID-19現在及預測的市場分析(2020-2030)

第10章 現在及未來的競爭情形

第11章 風險補正的淨現值法(NPV法)分析

目錄

GervanoRA's pipeline analysis and opportunity assessment report " Coronavirus Disease 2019 (COVID-19) - Curative Therapeutics for Acute & Chronic Complications with Current and Forecasted Market Analysis 2020 - 2030" analysed and assessed Coronavirus Disease 2019 (COVID-19) pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules and vaccines in different stages of development and all the companies which are actively involved in COVID-19 therapeutics and vaccines industry. The report has further segmented the therapeutics by the Complication types (Acute and Chronic Complications).

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the COVID-19 disease area. The report delivers an in-depth understanding of the COVID-19 historical and forecasted epidemiology based market trends Worldwide, the United States along with EU7 (Russia, United Kingdom (UK), France, Italy, Spain, Germany and Poland). A detailed analytics on the Current COVID-19 Market (2020) and the Forecasted COVID-19 Market until the year 2030 for the regions have been provided based on the Complication types - Acute and Chronic. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal.

The report provides detailed insights about all the pipeline molecules and vaccines in different stages of development and all the companies which are actively involved in COVID-19 drugs and vaccines industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of Development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Molecule Target, Pipeline Analytics by Drug Development Type and Pipeline Analytics by Company Type.

Our comprehensive analysis on the COVID-19 pipeline identified around 920 therapeutics and vaccines undergoing different stages of development- from Early R&D to In-Approval stage. Among these, a total of 573 are therapeutics and the count for total vaccines under development is 345. The report also aims to provide analytics and deep insights on the expected market share of the key clinical stage pipeline drugs for a better understanding of the COVID-19 market in the coming years and know the competition which is paramount for any new entrant.

The report has covered more than 850 companies worldwide, involved in the development of new therapeutics and vaccines. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 10 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Market Dynamics with Coverage of Deals (Licensing, Partnering, Collaborations, Financing etc.)
  • Pipeline Analysis of all Drug Molecules and Estimated Pipeline Drug Approval Time lines of Clinical Stage Pipeline Drug Candidates
  • Clinical Stage Drug Candidates' Descriptions along with Development Milestones
  • Current and Forecasted Market Analysis Based on the Therapeutics for the Acute and Chronic Complication Types
  • Plotting of the Anticipated Market Share for the New Entrants
  • Opportunity Assessments through Competitive Benchmarking
  • Evaluate Current and Future Competitive Landscape through Company Profiles
  • Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 01: INTRODUCTION

CHAPTER 02: EXECUTIVE SUMMARY

CHAPTER 03: CORONAVIRUS DISEASE 2019 (COVID-19) OVERVIEW AND EPIDEMIOLOGY STUDIES

CHAPTER 04: DEALS ANALYTICS OF COVID-19 COMPETITIVE SPACE

CHAPTER 05: PIPELINE DRUGS ANALYTICS OF CORONAVIRUS DISEASE 2019 (COVID-19)

CHAPTER 06: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

CHAPTER 07: ESTIMATED APPROVAL TIMELINES OF COVID-19 PIPELINE DRUGS

CHAPTER 08: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

CHAPTER 09: COVID-19 CURRENT AND FORECASTED MARKET ANALYSIS 2020-2030

CHAPTER 10: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

CHAPTER 11: RISK-ADJUSTED NET PRESENT VALUE (RNPV) ANALYSIS

LIST OF TABLES

  • TABLE 1: COVID-19 REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 2: PROMISING PIPELINE DRUG CANDIDATES PREDICTED TO BE APPROVED BY YEAR END OF 2022
  • TABLE 3: COMPANIES IN THE COVID-19 PIPELINE SEEKING EMERGENCY USE AUTHORISATIONS
  • TABLE 4: COMPANIES GRANTED OR SEEKING FAST TRACK DESIGNATIONS FOR COVID-19 THERAPEUTICS
  • TABLE 5: TREATMENTS APPROVED GLOBALLY FOR COVID-19
  • TABLE 6: TREATMENTS RECEIVING EMERGENCY USE AUTHORISATION FOR COVID-19
  • TABLE 7: COLLABORATION DEALS IN COVID-19 THERAPEUTIC AREA
  • TABLE 8: FINANCING DEALS IN COVID-19 THERAPEUTIC AREA
  • TABLE 9: LICENSING DEALS IN COVID-19 THERAPEUTIC AREA
  • TABLE 10: MERGER AND ACQUISITION DEALS IN COVID-19 THERAPEUTIC AREA
  • TABLE 11: CORONAVIRUS DISEASE 2019 (COVID-19) THERAPEUTIC PIPELINE DRUGS FOR CHRONIC COMPLICATIONS
  • TABLE 12: COVID-19 PHASE II/III & III PIPELINE MOLECULES FOR THE TREATMENT OF ACUTE COMPLICATIONS (SYMPTOMS)
  • TABLE 13: COVID-19 PHASE I/II & II PIPELINE MOLECULES FOR THE TREATMENT OF ACUTE COMPLICATIONS (SYMPTOMS)
  • TABLE 14: COVID-19 PHASE IB & I PIPELINE MOLECULES FOR THE TREATMENT OF ACUTE COMPLICATIONS (SYMPTOMS)
  • TABLE 15: COVID-19 PRE-CLINICAL PIPELINE MOLECULES FOR THE TREATMENT OF ACUTE COMPLICATIONS (SYMPTOMS)
  • TABLE 16: COVID-19 EARLY R&D PIPELINE MOLECULES FOR THE TREATMENT OF ACUTE COMPLICATIONS (SYMPTOMS)
  • TABLE 17: COVID-19 IN-APPROVAL PIPELINE DRUGS WITH ANTI-VIRAL ACTIVITY (TREATMENT & CHRONIC COMPLICATIONS)
  • TABLE 18: COVID-19 PHASE II/III & III STAGE DRUGS WITH ANTI-VIRAL ACTIVITY (TREATMENT & CHRONIC COMPLICATIONS)
  • TABLE 19: COVID-19 PHASE I/II & II STAGE DRUGS WITH ANTI-VIRAL ACTIVITY (TREATMENT & CHRONIC COMPLICATIONS)
  • TABLE 20: COVID-19 PHASE I STAGE DRUGS WITH ANTI-VIRAL ACTIVITY (TREATMENT & CHRONIC COMPLICATIONS)
  • TABLE 21: COVID-19 PRE-CLINICAL PIPELINE DRUGS WITH ANTI-VIRAL ACTIVITY (TREATMENT & CHRONIC COMPLICATIONS)
  • TABLE 22: COVID-19 EARLY R&D PIPELINE DRUGS WITH ANTI-VIRAL ACTIVITY (TREATMENT & CHRONIC COMPLICATIONS)
  • TABLE 23: ACUTE COMPLICATIONS PIPELINE DRUGS WITH PARENTERAL ROUTE OF ADMINISTRATION
  • TABLE 24: ACUTE COMPLICATIONS PIPELINE DRUGS WITH ORAL ROUTE OF ADMINISTRATION
  • TABLE 25: ANTI-VIRAL (CHRONIC COMPLICATIONS) PIPELINE DRUGS WITH PARENTERAL ROUTE OF ADMINISTRATION
  • TABLE 26: ANTI-VIRAL (CHRONIC COMPLICATIONS) PIPELINE DRUGS WITH ORAL ROUTE OF ADMINISTRATION
  • TABLE 27: LIST OF ANTIVIRAL THERAPEUTICS UNDER DEVELOPMENT
  • TABLE 28: LIST OF ANTIBODY-BASED THERAPEUTICS UNDER DEVELOPMENT
  • TABLE 29: LIST OF SMALL MOLECULE THERAPEUTICS UNDER DEVELOPMENT
  • TABLE 30: LIST OF CELL THERAPIES UNDER DEVELOPMENT
  • TABLE 31: LIST OF VACCINES UNDER DEVELOPMENT
  • TABLE 32: LIST OF CLINICAL STAGE PIPELINE MOLECULES WITH THEIR MECHANISM OF ACTIONS
  • TABLE 33: LIST OF NON-CLINICAL STAGE PIPELINE MOLECULES WITH THEIR MECHANISM OF ACTIONS
  • TABLE 34: LIST OF CLINICAL STAGE PIPELINE MOLECULES WITH THEIR MOLECULAR TARGETS
  • TABLE 35: LIST OF NON-CLINICAL STAGE PIPELINE MOLECULES WITH THEIR MOLECULAR TARGETS
  • TABLE 36: COVID-19 PIPELINE DRUGS ANALYTICS BY COMPANY TYPE
  • TABLE 37: REGION WISE STATISTICS, COMPANY COUNT WITH COUNT OF COVID-19 PIPELINE CANDIDATES
  • TABLE 38: GERVANORA ESTIMATED APPROVAL TIMELINES V/S ACTUAL APPROVAL DATE
  • TABLE 39: PROMINENT IND'S RECEIVING EMERGENCY USE AUTHORIZATIONS AND FAST TRACK DESIGNATIONS
  • TABLE 40: PROMISING REPURPOSED DRUGS IN EARLY CLINICAL STAGE (PHASE I AND PHASE I/II) TO APPROVE SOON
  • TABLE 41: PHASE II STAGE DRUGS RECEIVING EMERGENCY USE AUTHORIZATIONS AND FAST TRACK DESIGNATIONS
  • TABLE 42: PROMISING REPURPOSED DRUGS IN PHASE II STAGE OF DEVELOPMENT
  • TABLE 43: PROMISING PHASE II/III STAGE DRUGS RECEIVING EUA AND FAST TRACK DESIGNATIONS
  • TABLE 44: PROMISING REPURPOSED DRUGS IN PHASE II/III STAGE OF DEVELOPMENT
  • TABLE 45: PROMISING PHASE III STAGE DRUGS RECEIVING EUA AND FAST TRACK DESIGNATIONS
  • TABLE 46: PROMISING REPURPOSED DRUGS IN PHASE III STAGE OF DEVELOPMENT
  • TABLE 47: IN-APPROVAL STAGE COVID-19 THERAPEUTICS ANTICIPATING MARKET ENTRY SOON
  • TABLE 48: PROMISING PRE-CLINICAL STAGE COVID-19 THERAPEUTICS ANTICIPATING TO ENTER CLINICALS
  • TABLE 49: LIST OF EMERGING COMPANIES WITH REGULATORY ALLOWANCES FOR COVID-19 AND ASSOCIATED INDICATIONS
  • TABLE 50: COVID-19 GLOBAL MAXIMUM FORECASTED MARKET POTENTIAL
  • TABLE 51: COVID-19 GLOBAL CURRENT MARKET FOR ACUTE COMPLICATIONS THERAPEUTICS (2020)
  • TABLE 52: COVID-19 GLOBAL MARKET FOR ACUTE COMPLICATIONS THERAPEUTICS (2021)
  • TABLE 53: COVID-19 GLOBAL MARKET FOR ACUTE COMPLICATIONS THERAPEUTICS (2022)
  • TABLE 54: COVID-19 GLOBAL MARKET FOR ACUTE COMPLICATIONS THERAPEUTICS (2023)
  • TABLE 55: COVID-19 GLOBAL MARKET FOR ACUTE COMPLICATIONS THERAPEUTICS (2024)
  • TABLE 56: COVID-19 GLOBAL MARKET FOR ACUTE COMPLICATIONS THERAPEUTICS (2025)
  • TABLE 57: COVID-19 GLOBAL MARKET FOR ACUTE COMPLICATIONS THERAPEUTICS (2026)
  • TABLE 58: COVID-19 GLOBAL MARKET FOR ACUTE COMPLICATIONS THERAPEUTICS (2027)
  • TABLE 59: COVID-19 GLOBAL MARKET FOR ACUTE COMPLICATIONS THERAPEUTICS (2028)
  • TABLE 60: COVID-19 GLOBAL MARKET FOR ACUTE COMPLICATIONS THERAPEUTICS (2029)
  • TABLE 61: COVID-19 GLOBAL MARKET FOR ACUTE COMPLICATIONS THERAPEUTICS (2030)
  • TABLE 62: COMPARISON OF COVID-19 MARKET VALUES OF ACUTE COMPLICATIONS DRUGS, GLOBAL VS USA (BN USD)
  • TABLE 63: COMPARISON OF COVID-19 MARKET VALUES OF ACUTE COMPLICATIONS DRUGS, GLOBAL VS RUSSIA (BN USD)
  • TABLE 64: COMPARISON OF COVID-19 MARKET VALUES OF ACUTE COMPLICATIONS DRUGS, GLOBAL VS UK(BN USD)
  • TABLE 65: COMPARISON OF COVID-19 MARKET VALUES OF ACUTE COMPLICATIONS DRUGS, GLOBAL VS FRANCE (BN USD)
  • TABLE 66: COMPARISON OF COVID-19 MARKET VALUES OF ACUTE COMPLICATIONS DRUGS, GLOBAL VS ITALY (BN USD)
  • TABLE 67: COMPARISON OF COVID-19 MARKET VALUES OF ACUTE COMPLICATIONS DRUGS, GLOBAL VS SPAIN (BN USD)
  • TABLE 68: COMPARISON OF COVID-19 MARKET VALUES OF ACUTE COMPLICATIONS DRUGS, GLOBAL VS GERMANY(BN USD)
  • TABLE 69: COMPARISON OF COVID-19 MARKET VALUES OF ACUTE COMPLICATIONS DRUGS, GLOBAL VS POLAND (BN USD)
  • TABLE 70: COMPARISON OF COVID-19 MARKET VALUES OF CHRONIC COMPLICATIONS DRUGS, GLOBAL VS USA (BN USD)
  • TABLE 71: COMPARISON OF COVID-19 MARKET VALUES OF CHRONIC COMPLICATIONS DRUGS, GLOBAL VS RUSSIA (BN USD)
  • TABLE 72: COMPARISON OF COVID-19 MARKET VALUES OF CHRONIC COMPLICATIONS DRUGS, GLOBAL VS UK (BN USD)
  • TABLE 73: COMPARISON OF COVID-19 MARKET VALUES OF CHRONIC COMPLICATIONS DRUGS, GLOBAL VS FRANCE (BN $)
  • TABLE 74: COMPARISON OF COVID-19 MARKET VALUES OF CHRONIC COMPLICATIONS DRUGS, GLOBAL VS ITALY (BN USD)
  • TABLE 75: COMPARISON OF COVID-19 MARKET VALUES OF CHRONIC COMPLICATIONS DRUGS, GLOBAL VS SPAIN (BN USD)
  • TABLE 76: COMPARISON OF COVID-19 MARKET VALUES OF CHRONIC COMPLICATIONS DRUGS, GLOBAL VS GERMANY (BN $)
  • TABLE 77: COMPARISON OF COVID-19 MARKET VALUES OF CHRONIC COMPLICATIONS DRUGS, GLOBAL VS POLAND (BN $)
  • TABLE 78: PIPELINE ASSETS OF INOVIO WITH RESPECT TO HPV-TARGETED TREATMENTS
  • TABLE 79: PIPELINE ASSETS OF INOVIO WITH RESPECT TO IMMUNO-ONCOLOGY
  • TABLE 80: PIPELINE ASSETS OF INOVIO WITH RESPECT TO INFECTIOUS DISEASE
  • TABLE 81: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF INOVIO
  • TABLE 82: PIPELINE ASSETS OF NOVAVAX
  • TABLE 83: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF NOVAVAX
  • TABLE 84: PRESENTATION AND EVENTS OF NOVAVAX
  • TABLE 85: PIPELINE ASSETS OF DYNAVAX
  • TABLE 86: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF DYNAVAX
  • TABLE 87: PIPELINE ASSETS OF CLOVER
  • TABLE 88: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF CLOVER
  • TABLE 89: PIPELINE ASSETS OF HEAT BIOLOGICS
  • TABLE 90: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF HEAT BIOLOGICS
  • TABLE 91: PRESENTATION AND EVENTS OF HEAT BIOLOGICS
  • TABLE 92: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF PREDICTIVE ONCOLOGY
  • TABLE 93: PIPELINE ASSETS OF SORRENTO WITH RESPECT TO IMMUNO-ONCOLOGY
  • TABLE 94: PIPELINE ASSETS OF SORRENTO WITH RESPECT TO PAIN
  • TABLE 95: PIPELINE ASSETS OF SORRENTO WITH RESPECT TO LYMPHATIC DELIVERY
  • TABLE 96: PIPELINE ASSETS OF SORRENTO WITH RESPECT TO COVID-19
  • TABLE 97: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF SORRENTO
  • TABLE 98: PRESENTATION AND EVENTS OF SORRENTO
  • TABLE 99: PIPELINE ASSETS OF VAXART
  • TABLE 100: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF VAXART
  • TABLE 101: PIPELINE ASSETS OF ENTOS PHARMACEUTICALS UNDER ONCOLOGY
  • TABLE 102: PIPELINE ASSETS OF ENTOS PHARMACEUTICALS UNDER COVID-19
  • TABLE 103: PATENTS AND PATENT APPLICATIONS FILED BY ENTOS PHARMACEUTICALS
  • TABLE 104: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF ENTOS PHARMACEUTICALS
  • TABLE 105: PIPELINE ASSETS OF ATHERSYS
  • TABLE 106: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF ATHERSYS
  • TABLE 107: PRESENTATIONS AND EVENTS OF ATHERSYS
  • TABLE 108: PIPELINE ASSETS OF IMMUNIC THERAPEUTICS
  • TABLE 109: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENT OF IMMUNIC THERAPEUTICS
  • TABLE 110: PIPELINE ASSETS OF CYTODYN WITH RESPECT TO HIV
  • TABLE 111: PIPELINE ASSETS OF CYTODYN WITH RESPECT TO CANCER
  • TABLE 112: PIPELINE ASSETS OF CYTODYN WITH RESPECT TO IMMUNOLOGY
  • TABLE 113: PATENT PORTFOLIO OF CYTODYN
  • TABLE 114: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF CYTODYN
  • TABLE 115: PIPELINE ASSETS OF FARON PHARMACEUTICALS WITH RESPECT TO IMMUNO-ONCOLOGY
  • TABLE 116: PIPELINE ASSETS OF FARON PHARMACEUTICALS WITH RESPECT TO IMMUNOLOGY
  • TABLE 117: PATENT FAMILIES OWNED BY FARON PHARMACEUTICALS CONSIDERING TRAUMAKINE
  • TABLE 118: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF FARON PHARMACEUTICALS
  • TABLE 119: PIPELINE ASSETS OF CTI BIOPHARMA
  • TABLE 120: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF CTI BIOPHARMA
  • TABLE 121: PRESENTATIONS AND EVENTS OF CTI BIOPHARMA
  • TABLE 122: PIPELINE ASSETS OF RELIEF THERAPEUTICS
  • TABLE 123: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF RELIEF THERAPEUTICS
  • TABLE 124: PIPELINE ASSETS OF HUMANIGEN
  • TABLE 125: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF HUMANIGEN
  • TABLE 126: PRESENTATIONS AND EVENTS OF HUMANIGEN
  • TABLE 127: PIPELINE ASSETS OF DIMERIX
  • TABLE 128: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF DIMERIX
  • TABLE 129: PIPELINE ASSETS OF CALCIMEDICA
  • TABLE 130: PATENT FAMILIES OWNED BY CALCIMEDICA CONSIDERING CRAC INHIBITOR COMPOUNDS
  • TABLE 131: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF CALCIMEDICA
  • TABLE 132: PIPELINE ASSETS OF EVGEN PHARMA
  • TABLE 133: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF EVGEN PHARMA
  • TABLE 134: FACTORS CONSIDERED FOR R-NPV ANALYSIS OF 4P-021
  • TABLE 135: LIST OF PROMISING NEW ENTRANTS COMPETING TO EACH OTHER TO OCCUPY THE MARKET POTENTIAL IN 2027

LIST OF FIGURES

  • FIGURE 1: COVID-19 PIPELINE SPLIT BY THERAPEUTICS AND VACCINES
  • FIGURE 2: KEY EVENTS IN THE COVID-19 COMPETITIVE SPACE
  • FIGURE 3: GLOBAL COVID-19 INFECTED POPULATION FROM JANUARY 2020 TO MARCH 2021
  • FIGURE 4: EU7 COVID-19 INFECTED POPULATION FROM JANUARY 2020 TO MARCH 2021
  • FIGURE 5: WORLDWIDE COVID-19 2020 INFECTED POPULATION AND FORECASTED TO 2025 (VALUES ARE IN MILLIONS)
  • FIGURE 6: UNITED STATES COVID-19 2020 INFECTED POPULATION AND FORECASTED TO 2025 (VALUES ARE IN MILLIONS)
  • FIGURE 7: RUSSIA COVID-19 2020 INFECTED POPULATION AND FORECASTED TO 2025 (VALUES ARE IN MILLIONS)
  • FIGURE 8: UNITED KINGDOM COVID-19 2020 INFECTED POPULATION AND FORECASTED TO 2025 (VALUES ARE IN MILLIONS)
  • FIGURE 9: FRANCE COVID-19 2020 INFECTED POPULATION AND FORECASTED TO 2025 (VALUES ARE IN MILLIONS)
  • FIGURE 10: ITALY COVID-19 2020 INFECTED POPULATION AND FORECASTED TO 2025 (VALUES ARE IN MILLIONS)
  • FIGURE 11: SPAIN COVID-19 2020 INFECTED POPULATION AND FORECASTED TO 2025 (VALUES ARE IN MILLIONS)
  • FIGURE 12: GERMANY COVID-19 2020 INFECTED POPULATION AND FORECASTED TO 2025 (VALUES ARE IN MILLIONS)
  • FIGURE 13: POLAND COVID-19 2020 INFECTED POPULATION AND FORECASTED TO 2025 (VALUES ARE IN MILLIONS)
  • FIGURE 14: COVID-19 DEALS ANALYTICS BY DEAL TYPE
  • FIGURE 15: COVID-19 TREATMENT OPTION RELATED DEALS ANALYTICS UNDER COLLABORATION DEALS
  • FIGURE 16: KEY PLAYERS UNDER COVID-19 RELATED COLLABORATION DEALS
  • FIGURE 17: ANALYTICS OF KEY PLAYERS BASED ON FUNDING RECEIVED FOR COVID-19 TREATMENT
  • FIGURE 18: KEY PLAYERS UNDER COVID-19 RELATED LICENSING DEALS
  • FIGURE 19: LICENSING DEALS ANALYTICS BY TREATMENT TYPES
  • FIGURE 20: DEALS ANALYTICS BASED ON COMPLICATION TYPE
  • FIGURE 21: NUMERICAL REPRESENTATION OF DEAL TYPES FOR VACCINES
  • FIGURE 22: DEALS ANALYTICS CONCERNING SORRENTO THERAPEUTICS
  • FIGURE 23: COVID-19 DEALS ANALYTICS BY CONSIDERING QUARTERLY FREQUENCY
  • FIGURE 24: DEALS ANALYTICS BY ACTIVE PLAYERS
  • FIGURE 25: DEALS ANALYTICS OF GLAXOSMITHKLINE IN COVID-19 THERAPEUTIC AREA
  • FIGURE 26: DEALS ANALYTICS OF PFIZER IN COVID-19 THERAPEUTIC AREA
  • FIGURE 27: PIPELINE MOLECULES - CLINICAL VS PRECLINICAL & EARLY R&D
  • FIGURE 28: TOTAL PIPELINE MOLECULES VS COMPLICATION TYPE
  • FIGURE 29: PIPELINE DRUGS FOR THE TREATMENT OF ACUTE COMPLICATIONS
  • FIGURE 30: PIPELINE DRUGS INDICATED FOR THE TREATMENT OF ACUTE & CHRONIC COMPLICATIONS VS STAGE OF DEVELOPMENT
  • FIGURE 31: PHASE I/II, II PIPELINE DRUGS INDICATED FOR THE TREATMENT OF ACUTE COMPLICATIONS TYPES
  • FIGURE 32: PHASE I/II AND PHASE II MOLECULES SPLIT BY ANTI-VIRAL ACTIVITY
  • FIGURE 33: PHASE I MOLECULES SPLIT BY ANTI-VIRAL ACTIVITY
  • FIGURE 34: COVID-19 DRUGS PIPELINE ANALYTICS BY ROA
  • FIGURE 35: COVID-19 DRUGS PIPELINE ANALYTICS BY PARENTERAL ROA
  • FIGURE 36: ACUTE COMPLICATIONS PIPELINE DRUGS ANALYTICS BY ROA
  • FIGURE 37: ACUTE COMPLICATIONS PIPELINE DRUGS ANALYTICS BY PARENTERAL ROA
  • FIGURE 38: ACUTE COMPLICATIONS PARENTERAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 39: ACUTE COMPLICATIONS ORAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 40: ANTI-VIRAL MOLECULES (CHRONIC COMPLICATIONS) PIPELINE DRUGS ANALYTICS BY ROA
  • FIGURE 41: ANTI-VIRAL (CHRONIC COMPLICATIONS) PIPELINE DRUGS ANALYTICS BY PARENTERAL ROA
  • FIGURE 42: ANTI-VIRAL (CHRONIC COMPLICATIONS) PARENTERAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 43: ANTI-VIRAL ORAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 44: TOTAL PIPELINE MOLECULES V/S DRUG CLASSES
  • FIGURE 45: ANALYTICS BY VACCINES TYPE
  • FIGURE 46: PIPELINE DRUG CLASS ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 47: COVID-19 PIPELINE DRUGS BIOLOGICALS VS SMALL MOLECULES
  • FIGURE 48: COVID-19 PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE
  • FIGURE 49: COVID-19 PIPELINE DRUGS ANALYTICS BY REPURPOSED DRUGS, REDIRECTED DRUGS AND NBES/NCES
  • FIGURE 50: COVID-19 PIPELINE DRUGS ANALYTICS BY REPURPOSED DRUGS, NBES, NCES, REDIRECTED NBES AND REDIRECTED NCES
  • FIGURE 51: COVID-19 PIPELINE DRUGS ANALYTICS BY REPURPOSED DRUGS V/S HSD
  • FIGURE 52: COVID-19 PIPELINE DRUGS ANALYTICS BY REPURPOSED DRUGS V/S ROA AND MOLECULE TYPE
  • FIGURE 53: COVID-19 PIPELINE DRUGS ANALYTICS BY NEW BIOLOGICAL ENTITIES V/S HSD
  • FIGURE 54: COVID-19 PIPELINE DRUGS ANALYTICS BY NBES V/S ROA
  • FIGURE 55: COVID-19 PIPELINE DRUGS ANALYTICS BY NEW CHEMICAL ENTITIES V/S HSD
  • FIGURE 56: COVID-19 PIPELINE DRUGS ANALYTICS BY NCES V/S ROA
  • FIGURE 57: COVID-19 PIPELINE DRUGS ANALYTICS BY REDIRECTED NEW BIOLOGICAL ENTITIES V/S HSD
  • FIGURE 58: COVID-19 PIPELINE DRUGS ANALYTICS BY REDIRECTED NBES V/S ROA
  • FIGURE 59: COVID-19 PIPELINE DRUGS ANALYTICS BY REDIRECTED NEW CHEMICAL ENTITIES V/S HSD
  • FIGURE 60: COVID-19 PIPELINE DRUGS ANALYTICS BY REDIRECTED NCES V/S ROA
  • FIGURE 61: GEOGRAPHICAL CATEGORIZATION OF COMPANIES
  • FIGURE 62: COUNT OF COMPANIES WITH RESPECT TO THE THERAPY TYPE
  • FIGURE 63: TOP FIVE COMPANIES WITH RESPECT TO R&D EXPENSES INCURRED FOR COVID-19 THERAPEUTIC AREA
  • FIGURE 64: PIPELINE PORTFOLIO OF MAJOR COMPANIES WITH (NUMBER OF MOLECULES)
  • FIGURE 65: TIME LINE OF PATENT AND PATENT APPLICATION EXPIRIES WITH RESPECT TO COVID-19 TREATMENT
  • FIGURE 66: RANKING OF EMERGING COMPANIES CONSIDERING PARTNERING ACTIVITIES PERTAINING TO COVID-19
  • FIGURE 67: GLOBAL COVID-19 CURRENT (2020) AND FORECASTED MARKET FROM 2021 TO 2030 (BN USD)
  • FIGURE 68: COVID-19 TOTAL CURRENT MARKET (2020) AND FORECASTED MARKET (2021-2030) TREND SPLIT BY MAJOR MARKETS
  • FIGURE 69: GLOBAL COVID-19 FORECASTED MARKET BY COMPLICATION TYPES FROM 2021 TO 2030 (BN USD)
  • FIGURE 70: EIGHT MAJOR MARKET'S COVID-19 MARKET BY COMPLICATIONS TYPE FOR THE YEAR 2030 IN BN USD
  • FIGURE 71: COMPARISON OF COVID-19 MARKET FOR ACUTE COMPLICATIONS THERAPEUTICS GLOBAL & EIGHT MAJOR MARKETS (BN $)
  • FIGURE 72: YEAR WISE MARKET VALUES OF COVID-19 GLOBAL MARKET FOR ACUTE COMPLICATIONS THERAPEUTICS (BN USD)
  • FIGURE 73: YEAR WISE MARKET TREND OF COVID-19 GLOBAL MARKET BY MAJOR ACUTE COMPLICATIONTYPES
  • FIGURE 74: GLOBAL MARKET VALUES FOR ACUTE COMPLICATION THERAPEUTICS IN 2020 (MILLION USD)
  • FIGURE 75: GLOBAL MARKET VALUES FOR ACUTE COMPLICATION THERAPEUTICS IN 2021 (MILLION USD)
  • FIGURE 76: GLOBAL MARKET VALUES FOR ACUTE COMPLICATION THERAPEUTICS IN 2022 (MILLION USD)
  • FIGURE 77: GLOBAL MARKET VALUES FOR ACUTE COMPLICATION THERAPEUTICS IN 2023 (MILLION USD)
  • FIGURE 78: GLOBAL MARKET VALUES FOR ACUTE COMPLICATION THERAPEUTICS IN 2024 (MILLION USD)
  • FIGURE 79: GLOBAL MARKET VALUES FOR ACUTE COMPLICATION THERAPEUTICS IN 2025 (MILLION USD)
  • FIGURE 80: GLOBAL MARKET VALUES FOR ACUTE COMPLICATION THERAPEUTICS IN 2026 (MILLION USD)
  • FIGURE 81: GLOBAL MARKET VALUES FOR ACUTE COMPLICATION THERAPEUTICS IN 2027 (MILLION USD)
  • FIGURE 82: GLOBAL MARKET VALUES FOR ACUTE COMPLICATION THERAPEUTICS IN 2028 (MILLION USD)
  • FIGURE 83: GLOBAL MARKET VALUES FOR ACUTE COMPLICATION THERAPEUTICS IN 2029 (MILLION USD)
  • FIGURE 84: GLOBAL MARKET VALUES FOR ACUTE COMPLICATION THERAPEUTICS IN 2030 (MILLION USD)
  • FIGURE 85: SPLITUP OF THE COVID-19 MARKET FOR ACUTE COMPLICATIONS DRUGS, THE US AND SEVEN EUROPEAN MAJOR MARKETS
  • FIGURE 86: GEOGRAPHICAL COMPARISON OF COVID-19 MARKET OF ACUTE COMPLICATION THERAPEUTICS, 2020 V/S 2030 IN BN USD
  • FIGURE 87: US CURRENT (2020) COVID-19 MARKET OF ACUTE COMPLICATION DRUGS COMPARED WITH GLOBAL MARKET (BN USD)
  • FIGURE 88: US CURRENT MARKET VALUES FOR MAJOR ACUTE COMPLICATION TYPES (MILLION USD)
  • FIGURE 89: COMPARISON OF COVID-19 MARKET OF ACUTE COMPLICATION DRUGS, GLOBAL VS USA (2020 - 2030) (BN USD)
  • FIGURE 90: RUSSIA CURRENT (2020) COVID-19 MARKET OF ACUTE COMPLICATION DRUGS COMPARED WITH GLOBAL MARKET (BN USD)
  • FIGURE 91: RUSSIA CURRENT MARKET VALUES FOR MAJOR ACUTE COMPLICATION TYPES (MILLION USD)
  • FIGURE 92: COMPARISON OF COVID-19 MARKET OF ACUTE COMPLICATION DRUGS, GLOBAL VS RUSSIA (2020 - 2030) (BN USD)
  • FIGURE 93: UK CURRENT (2020) COVID-19 MARKET OF ACUTE COMPLICATION DRUGS COMPARED WITH GLOBAL MARKET (BN USD)
  • FIGURE 94: UNITED KINGDOM CURRENT MARKET VALUES FOR MAJOR ACUTE COMPLICATION TYPES (MILLION USD)
  • FIGURE 95: COMPARISON OF COVID-19 MARKET OF ACUTE COMPLICATION DRUGS, GLOBAL VS UK (2020 - 2030) (BN USD)
  • FIGURE 96: FRANCE CURRENT (2020) COVID-19 MARKET OF ACUTE COMPLICATION DRUGS COMPARED WITH GLOBAL MARKET (BN USD)
  • FIGURE 97: FRANCE CURRENT MARKET VALUES FOR MAJOR ACUTE COMPLICATION TYPES (MILLION USD)
  • FIGURE 98: COMPARISON OF COVID-19 MARKET OF ACUTE COMPLICATION DRUGS, GLOBAL VS FRANCE (2020 - 2030) (BN USD)
  • FIGURE 99: ITALY CURRENT (2020) COVID-19 MARKET OF ACUTE COMPLICATION DRUGS COMPARED WITH GLOBAL MARKET (BN USD)
  • FIGURE 100: ITALY CURRENT MARKET VALUES FOR MAJOR ACUTE COMPLICATION TYPES (MILLION USD)
  • FIGURE 101: COMPARISON OF COVID-19 MARKET OF ACUTE COMPLICATION DRUGS, GLOBAL VS ITALY (2020 - 2030) (BN USD)
  • FIGURE 102: SPAIN CURRENT (2020) COVID-19 MARKET OF ACUTE COMPLICATION DRUGS COMPARED WITH GLOBAL MARKET (BN USD)
  • FIGURE 103: SPAIN CURRENT MARKET VALUES FOR MAJOR ACUTE COMPLICATION TYPES (MILLION USD)
  • FIGURE 104: COMPARISON OF COVID-19 MARKET OF ACUTE COMPLICATION DRUGS, GLOBAL VS SPAIN (2020 - 2030) (BN USD)
  • FIGURE 105: GERMANY CURRENT (2020) COVID-19 MARKET OF ACUTE COMPLICATION DRUGS COMPARED WITH GLOBAL MARKET (BN $)
  • FIGURE 106: GERMANY CURRENT MARKET VALUES FOR MAJOR ACUTE COMPLICATION TYPES (MILLION USD)
  • FIGURE 107: COMPARISON OF COVID-19 MARKET OF ACUTE COMPLICATION DRUGS, GLOBAL VS GERMANY (2020 - 2030) (BN USD)
  • FIGURE 108: POLAND CURRENT (2020) COVID-19 MARKET OF ACUTE COMPLICATION DRUGS COMPARED WITH GLOBAL MARKET (BN $)
  • FIGURE 109: POLAND CURRENT MARKET VALUES FOR MAJOR ACUTE COMPLICATION TYPES (MILLION USD)
  • FIGURE 110: COMPARISON OF COVID-19 MARKET OF ACUTE COMPLICATION DRUGS, GLOBAL VS POLAND (2020 - 2030) (BN USD)
  • FIGURE 111: COMPARISON OF COVID-19 MARKET FOR CHRONIC COMPLICATIONS DRUGS, GLOBAL & EIGHT MAJOR MARKETS (BN USD)
  • FIGURE 112: YEAR WISE MARKET VALUES OF COVID-19 GLOBAL MARKET FOR CHRONIC COMPLICATIONS THERAPEUTICS IN BN USD
  • FIGURE 113: YEAR WISE MARKET TREND OF COVID-19 GLOBAL MARKET BY MAJOR CHRONIC COMPLICATIONS TYPES
  • FIGURE 114: COMPARISON OF GLOBAL MARKET FOR CHRONIC COMPLICATION DRUGS & GLOBAL COVID-19 MARKET (2021) IN MILLION $
  • FIGURE 115: COVID-19 GLOBAL MARKET FOR CHRONIC COMPLICATIONS DRUGS SPLIT-UP BY MAJOR MARKET AREAS, 2021 (MILLION $)
  • FIGURE 116: COMPARISON OF GLOBAL MARKET FOR CHRONIC COMPLICATION DRUGS & GLOBAL COVID-19 MARKET (2022) IN MILLION $
  • FIGURE 117: COVID-19 GLOBAL MARKET FOR CHRONIC COMPLICATIONS DRUGS SPLIT-UP BY MAJOR MARKET AREAS, 2022 (MILLION $)
  • FIGURE 118: COMPARISON OF GLOBAL MARKET FOR CHRONIC COMPLICATION DRUGS & GLOBAL COVID-19 MARKET (2023) IN MILLION $
  • FIGURE 119: COVID-19 GLOBAL MARKET FOR CHRONIC COMPLICATIONS DRUGS SPLIT-UP BY MAJOR MARKET AREAS, 2023 (MILLION $)
  • FIGURE 120: COMPARISON OF GLOBAL MARKET FOR CHRONIC COMPLICATION DRUGS & GLOBAL COVID-19 MARKET (2024) IN MILLION $
  • FIGURE 121: COVID-19 GLOBAL MARKET FOR CHRONIC COMPLICATIONS DRUGS SPLIT-UP BY MAJOR MARKET AREAS, 2024 (MILLION $)
  • FIGURE 122: COMPARISON OF GLOBAL MARKET FOR CHRONIC COMPLICATION DRUGS & GLOBAL COVID-19 MARKET (2025) IN MILLION $
  • FIGURE 123: COVID-19 GLOBAL MARKET FOR CHRONIC COMPLICATIONS DRUGS SPLIT-UP BY MAJOR MARKET AREAS, 2025 (MILLION $)
  • FIGURE 124: COMPARISON OF GLOBAL MARKET FOR CHRONIC COMPLICATION DRUGS & GLOBAL COVID-19 MARKET (2026) IN MILLION $
  • FIGURE 125: COVID-19 GLOBAL MARKET FOR CHRONIC COMPLICATIONS DRUGS SPLIT-UP BY MAJOR MARKET AREAS, 2026 (MILLION $)
  • FIGURE 126: COMPARISON OF GLOBAL MARKET FOR CHRONIC COMPLICATION DRUGS & GLOBAL COVID-19 MARKET (2027) IN MILLION $
  • FIGURE 127: COVID-19 GLOBAL MARKET FOR CHRONIC COMPLICATIONS DRUGS SPLIT-UP BY MAJOR MARKET AREAS, 2027 (MILLION $)
  • FIGURE 128: COMPARISON OF GLOBAL MARKET FOR CHRONIC COMPLICATION DRUGS & GLOBAL COVID-19 MARKET (2028) IN MILLION $
  • FIGURE 129: COVID-19 GLOBAL MARKET FOR CHRONIC COMPLICATIONS DRUGS SPLIT-UP BY MAJOR MARKET AREAS, 2028 (MILLION $)
  • FIGURE 130: COMPARISON OF GLOBAL MARKET FOR CHRONIC COMPLICATION DRUGS & GLOBAL COVID-19 MARKET (2029) IN MILLION $
  • FIGURE 131: COVID-19 GLOBAL MARKET FOR CHRONIC COMPLICATIONS DRUGS SPLIT-UP BY MAJOR MARKET AREAS, 2029 (MILLION $)
  • FIGURE 132: COMPARISON OF GLOBAL MARKET FOR CHRONIC COMPLICATION DRUGS & GLOBAL COVID-19 MARKET (2030) IN MILLION $
  • FIGURE 133: COVID-19 GLOBAL MARKET FOR CHRONIC COMPLICATIONS DRUGS SPLIT-UP BY MAJOR MARKET AREAS, 2030 (MILLION $)
  • FIGURE 134: SPLITUP OF THE COVID-19 MARKET FOR CHRONIC COMPLICATIONS DRUGS - THE US AND EU7
  • FIGURE 135: GEOGRAPHICAL COMPARISON OF COVID-19 MARKET OF CHRONIC COMPLICATION THERAPEUTICS, 2021 V/S 2030 (BN USD)
  • FIGURE 136: US COVID-19 MARKET OF CHRONIC COMPLICATIONS DRUGS COMPARED WITH GLOBAL MARKET IN 2021 (BN USD)
  • FIGURE 137: US ESTIMATED MARKET VALUES IN 2021 FOR MAJOR CHRONIC COMPLICATION TYPES (MILLION USD)
  • FIGURE 138: COMPARISON OF COVID-19 MARKET OF CHRONIC COMPLICATIONS DRUGS, GLOBAL VS USA (2021 - 2030) (BN USD)
  • FIGURE 139: RUSSIA COVID-19 MARKET OF CHRONIC COMPLICATIONS DRUGS COMPARED WITH GLOBAL MARKET, 2021 (BN USD)
  • FIGURE 140: RUSSIA ESTIMATED MARKET VALUES IN 2021 FOR MAJOR CHRONIC COMPLICATION TYPES (MILLION USD)
  • FIGURE 141: COMPARISON OF COVID-19 MARKET OF CHRONIC COMPLICATION DRUGS, GLOBAL VS RUSSIA (2021 - 2030) (BN USD)
  • FIGURE 142: UK COVID-19 MARKET OF CHRONIC COMPLICATION DRUGS COMPARED WITH GLOBAL MARKET IN 2021 (BN USD)
  • FIGURE 143: UK ESTIMATED MARKET VALUES IN 2021 FOR MAJOR CHRONIC COMPLICATION TYPES (MILLION USD)
  • FIGURE 144: COMPARISON OF COVID-19 MARKET OF CHRONIC COMPLICATION DRUGS, GLOBAL VS UK (2021 - 2030) (BN USD)
  • FIGURE 145: FRANCE COVID-19 MARKET OF CHRONIC COMPLICATION DRUGS COMPARED WITH GLOBAL MARKET IN 2021 (BN USD)
  • FIGURE 146: FRANCE ESTIMATED MARKET VALUES IN 2021 FOR MAJOR CHRONIC COMPLICATION TYPES (MILLION USD)
  • FIGURE 147: COMPARISON OF COVID-19 MARKET OF CHRONIC COMPLICATION DRUGS, GLOBAL VS FRANCE (2021 - 2030) (BN USD)
  • FIGURE 148: ITALY COVID-19 MARKET OF CHRONIC COMPLICATION DRUGS COMPARED WITH GLOBAL MARKET IN 2021 (BN USD)
  • FIGURE 149: ITALY ESTIMATED MARKET VALUES IN 2021 FOR MAJOR CHRONIC COMPLICATION TYPES (MILLION USD)
  • FIGURE 150: COMPARISON OF COVID-19 MARKET OF CHRONIC COMPLICATION DRUGS, GLOBAL VS ITALY (2021 - 2030) (BN USD)
  • FIGURE 151: SPAIN COVID-19 MARKET OF CHRONIC COMPLICATION DRUGS COMPARED WITH GLOBAL MARKET IN 2021 (BN USD)
  • FIGURE 152: SPAIN ESTIMATED MARKET VALUES IN 2021 FOR MAJOR CHRONIC COMPLICATION TYPES (MILLION USD)
  • FIGURE 153: COMPARISON OF COVID-19 MARKET OF CHRONIC COMPLICATION DRUGS, GLOBAL VS SPAIN (2021 - 2030) (BN USD)
  • FIGURE 154: GERMANY COVID-19 MARKET OF CHRONIC COMPLICATION DRUGS COMPARED WITH GLOBAL MARKET IN 2021 (BN USD)
  • FIGURE 155: GERMANY ESTIMATED MARKET VALUES IN 2021 FOR MAJOR CHRONIC COMPLICATION TYPES (MILLION USD)
  • FIGURE 156: COMPARISON OF COVID-19 MARKET OF CHRONIC COMPLICATION DRUGS, GLOBAL VS GERMANY (2021 - 2030) (BN USD)
  • FIGURE 157: POLAND COVID-19 MARKET OF CHRONIC COMPLICATION DRUGS COMPARED WITH GLOBAL MARKET IN 2021 (BN USD)
  • FIGURE 158: POLAND ESTIMATED MARKET VALUES IN 2021 FOR MAJOR CHRONIC COMPLICATION TYPES (MILLION USD)
  • FIGURE 159: COMPARISON OF COVID-19 MARKET OF CHRONIC COMPLICATION DRUGS, GLOBAL VS POLAND (2021 - 2030) (BN USD)